Thrombosis in COVID-19.
Am J Hematol
; 95(12): 1578-1589, 2020 12.
Article
in En
| MEDLINE
| ID: mdl-32857878
ABSTRACT
Thrombotic complications are frequent in COVID-19 and contribute significantly to mortality and morbidity. We review several mechanisms of hypercoagulability in sepsis that may be upregulated in COVID-19. These include immune-mediated thrombotic mechanisms, complement activation, macrophage activation syndrome, antiphospholipid antibody syndrome, hyperferritinemia, and renin-angiotensin system dysregulation. We highlight biomarkers within each pathway with potential prognostic value in COVID-19. Lastly, recent observational studies have evaluated a role for the expanded use of therapeutic anticoagulation in COVID-19. We review strengths and weaknesses of these studies, and we also discuss the hypothetical benefit and anticipated challenges of fibrinolytic therapy in COVID-19.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Thrombosis
/
SARS-CoV-2
/
COVID-19
Type of study:
Observational_studies
Limits:
Humans
Language:
En
Journal:
Am J Hematol
Year:
2020
Document type:
Article
Affiliation country:
United States